Smoking cessation 3: Nicotinic partial agonists in smoking cessation - Varenicline and cytisine
Cigarette smoking is the most preventable cause of illness, death, and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this third article in our series on smoking cessation in primary care, we look at the evidence for the use of nicotinic par...
| Autors principals: | , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2009
|
| Sumari: | Cigarette smoking is the most preventable cause of illness, death, and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this third article in our series on smoking cessation in primary care, we look at the evidence for the use of nicotinic partial agonists, including cytisine, which is not yet available in this country, and varenicline, which is. |
|---|